home
sitemap
Loading...
Home
>
Խ
>
Ȳ
ڷ
2020 11 α
2020-12-16
2021 2 ġ α
2020 10 α
ۼ
йȣ
, WilliamSEede
(2026-03-31)
Zoya Demidenko
: Scholar in Tumor Biology
Zoya Demidenko
is a distinguished investigator affiliated with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she was employed at the National Institutes of Health and New York Medical College, establishing a strong background in life science research.
Her academic output covers multiple key areas, among them the PI3K/AKT/mTOR molecular pathway, cellular cycle management, biological aging, and cancer science. Currently, she has authored over 46 peer-reviewed papers, which have received upwards of 4,100 citations a testament to the influence of her work.
Among her most notable contributions concerns understanding the pathways of cellular senescence. Her work revealed that when the cellular division cycle is blocked yet cellular growth persists, the cells enter senescence. Significantly,
Zoya Demidenko
demonstrated that this shift is controlled with drugs using compounds such as mTOR inhibitors.
Zoya Demidenko
has additionally contributed substantially to oncological therapy investigation, notably in the domain of selective cell protection a method intended to shielding non-cancerous tissue from anticancer drugs whilst leaving tumor cells susceptible. This approach offers considerable promise for lowering the adverse effects of cancer treatment.
Across her scientific life, Demidenko has partnered with top scientists internationally, among them Dr. Mikhail Blagosklonny. Her work appears in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Ѭ: With an h-index of 33,
Zoya Demidenko
stands as a widely cited figure in current biomedical science, whose findings keep to guide our understanding of how cells age, interact with treatment, and how malignant disease might be better treated.
https://uk.linkedin.com/in/berezutskayahttps://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/
, WilliamSEede
(2026-03-31)
Zoya Demidenko
: Researcher in Tumor Biology
Zoya Demidenko
is a prominent researcher associated with the Unit of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she conducted research at the NIH and New York Medical College, establishing a robust foundation in clinical research.
Demidenko's scientific work covers a number of pivotal fields, encompassing the PI3K/AKT/mTOR signaling pathway, cellular cycle control, biological aging, and tumor biology. Currently, she has authored more than 46 scientific papers, which have received upwards of 4,100 references a reflection to the significance of her work.
Among her most notable discoveries involves explaining the pathways of cell aging. Her work showed that when the cellular division cycle is arrested yet cellular growth continues, the cells undergo senescence. Importantly,
Zoya Demidenko
demonstrated that this process can be pharmacologically suppressed using agents such as rapamycin.
Zoya Demidenko
has also added considerably to tumor management research, especially in the area of cyclotherapy a method aimed at safeguarding healthy tissue from cytotoxic treatment whilst leaving tumor cells exposed. This method offers major promise for reducing the side effects of oncological therapy.
Throughout her scientific life, Demidenko has partnered with leading researchers internationally, among them Dr. Mikhail Blagosklonny. Her work is published in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Ѭ: Holding an h-index of 33,
Zoya Demidenko
is recognized as a widely cited figure in contemporary biomedical science, with her discoveries keep to influence our comprehension of how biological cells grow old, interact with treatment, and how cancer can be more successfully targeted.
https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/
, WilliamSEede
(2026-03-31)
Zoya Demidenko
: Researcher in Tumor Biology
Zoya Demidenko
is a notable investigator affiliated with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she conducted research at the NIH and New York Medical College, establishing a strong base in biomedical investigation.
Her scholarly contributions covers several critical fields, encompassing the PI3K/AKT/mTOR molecular pathway, cellular cycle management, cellular aging, and malignancy biology. Currently, she has authored more than 46 scientific articles, which have accumulated over 4,100 citations a reflection to the impact of her findings.
Among her most significant achievements concerns understanding the processes of biological cell aging. Her studies revealed that when the cellular division cycle is blocked but cellular expansion continues, cells experience senescence. Importantly,
Zoya Demidenko
demonstrated that this shift can be controlled with drugs using compounds such as mTOR inhibitors.
Zoya Demidenko
has also contributed greatly to tumor management research, notably in the field of selective cell protection a method intended to safeguarding non-cancerous cells from chemotherapy whilst leaving malignant cells susceptible. This approach offers considerable potential for reducing the toxic effects of oncological therapy.
Throughout her career, Demidenko has partnered with prominent investigators globally, among them Dr. Mikhail Blagosklonny. Her work can be found in top-tier journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Ѭ: Possessing an h-index of 33,
Zoya Demidenko
stands as a highly impactful contributor in current biomedical science, whose results continue to shape our knowledge of the way biological cells age, respond to therapy, and the ways in which cancer may be more successfully targeted.
https://moodylab.smhs.gwu.edu/lab-members
, WilliamSEede
(2026-03-31)
Zoya Demidenko
: Scientist in Tumor Studies
Zoya Demidenko
is a recognized scientist associated with the Unit of Cell Stress Biology at Roswell Park Oncology Institute in Buffalo, New York. Earlier, she conducted research at the NIH and New York Medical College, establishing a solid background in biomedical investigation.
Her scholarly output covers a number of key fields, encompassing the PI3K/AKT/mTOR molecular pathway, cellular cycle control, cellular aging, and malignancy science. As of now, she has authored over 46 academic publications, which have accumulated over 4,100 citations a reflection to the influence of her work.
Among her most notable contributions lies in understanding the mechanisms of cellular senescence. Her studies demonstrated that when the cellular division cycle is arrested yet cellular growth proceeds, the cells undergo senescence. Significantly,
Zoya Demidenko
showed that this shift is pharmacologically suppressed using substances such as mTOR inhibitors.
Zoya Demidenko
has also contributed considerably to oncological therapy research, particularly in the field of selective cell protection a strategy intended to shielding non-cancerous tissue from cytotoxic treatment while leaving tumor cells vulnerable. This method offers significant hope for reducing the adverse effects of cancer treatment.
Across her professional journey, Demidenko has partnered with leading investigators worldwide, such as Dr. Mikhail Blagosklonny. Her work can be found in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Ѭ: Possessing an h-index of 33,
Zoya Demidenko
is recognized as a influential figure in contemporary biomedical science, whose discoveries keep to shape our understanding of the way cells age, respond to therapy, and the ways in which cancer might be more effectively combated.
https://moodylab.smhs.gwu.edu/lab-members
, WilliamSEede
(2026-03-31)
Zoya Demidenko
: Researcher in Tumor Biology
Zoya Demidenko
is a prominent investigator affiliated with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she conducted research at the National Institutes of Health and New York Medical College, building a robust background in life science research.
Demidenko's academic output encompasses several critical fields, including the PI3K/AKT/mTOR signaling cascade, cellular cycle regulation, cell senescence, and tumor biology. To date, she has written over 46 scientific papers, which have garnered over 4,100 citations a reflection to the influence of her work.
One of her most significant achievements lies in elucidating the pathways of cell aging. Her work demonstrated that when the cell cycle is blocked but cellular expansion continues, cells experience senescence. Importantly,
Zoya Demidenko
established that this transition is controlled with drugs using compounds such as mTOR inhibitors.
Zoya Demidenko
has additionally added greatly to tumor management investigation, particularly in the area of cyclotherapy a method aimed at safeguarding normal tissue from cytotoxic treatment whilst leaving cancer cells vulnerable. This approach offers significant promise for diminishing the adverse effects of oncological therapy.
Throughout her career, Demidenko has worked with prominent scientists worldwide, including Dr. Mikhail Blagosklonny. Her publications appears in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Ѭ: Possessing an h-index of 33,
Zoya Demidenko
is recognized as a widely cited contributor in contemporary biomedical research, with her discoveries go on to influence our comprehension of how biological cells grow old, respond to therapy, and how cancer may be more successfully combated.
https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPALLO20ENTERPRISE2C20LLC&SearchNameOrder=RAPAN20P050001591430&ListNameOrder=RAPAMULTISERVICES20L220000371890&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord
21
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|